<DOC>
	<DOCNO>NCT02990728</DOCNO>
	<brief_summary>Primary objective To discover efficacy levonorgestrel-containing intrauterine device ( LNG-IUS , Mirena® ) , without metformin , fertility-preserving treatment grade 1 endometrioid adenocarcinoma endometrium , cT1aN0M0 presume myometrial invasion image study ( MRI prefer ) . Secondary objective 1 . To discover morphological molecular change endometrium tumor treatment 2 . To discover effectiveness add oral progestin subject show good response assign 3 . To compare ( 1 ) systemic effect , include body weight change , neuropsychiatric alternation , GI disturbance , skin disorder , change serum metabolic hepatic marker two study patient group ; ( 2 ) The rate long-term success define ( ) sustain remission &gt; = 12 month start histologic documentation complete remission ( b ) rate pregnancy ( c ) alive baby delivery , base time-to-event analysis . 4 . Molecular marker expression , treatment , include progesterone B receptor , progesterone A receptor , estrogen receptor , Ki67 , PTEN relate marker , Bcl2 relate marker develop marker . This discover prediction marker medical treatment .</brief_summary>
	<brief_title>Mirena® ± Metformin Fertility-preserving Treatment Young Asian Women With Early Endometrial Cancer</brief_title>
	<detailed_description />
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Megestrol</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Megestrol Acetate</mesh_term>
	<mesh_term>Progestins</mesh_term>
	<criteria>1 . Women &lt; = 40 year old histologic confirm grade 1 endometrioid adenocarcinoma endometrium 2 . Tumour confirm endometrial cavity evidence metastasis MRI and/or transvaginal ultrasonography 3 . ECOG 01 , adequate organ function , fertility preserve need 4 . Immunohistochemical study show positive progesterone receptor positive estrogen receptor endometrial tumour tissue 5 . Serum CA 125 titre within normal limit 6 . Signed informed consent 1 . Women age &gt; 40 year endometrial cancer grade 1 endometrioid adenocarcinoma 2 . Suspected lymph node metastasis metastasis appear image study 3 . Ovarian tumour image study 4 . Blurred junction endometrium myometrium image study , impression myometrial invasion endometrial tumour rule 5 . Ultrasonographic study MRI show obvious adenomyosis ovarian endometriosis 6 . Women contraindicate receive study treatment intolerance treatment agent , medical comorbidity reason ( ) 7 . Women history concurrent malignancy skin basal cell carcinoma 8 . Women participate regular followup</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Endometrial Cancer.Mirena®</keyword>
</DOC>